Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Participants
Cystic Fibrosis|Aspergillosis - 8 Years to 17 Years (Child)
Interventions
Drug: Posaconazole 100 MG [Noxafil]|Drug: Posaconazole 40 MG/ML
Outcome measures
Pharmacokinetic parameters of posaconazole|Aspergillus isolation from sputum cultures|Patients with a favourable clinical response and no signs of Aspergillus infection|Patients with no signs of Aspergillus infection|The proportion of participants experiencing AEs and SAEs